Latest News

The developers expect the product to be available for order in the United States in early February 2025.
FDA Approves Axatilimab in 9 Mg and 22 Mg Vial Sizes for GVHD

January 16th 2025

The developers expect the product to be available for order in the United States in early February 2025.

Efficacy findings reveal that the phase 3 ARES study evaluating MaaT013 met its primary end point of gastrointestinal overall response rate.
MaaT013 Elicits Durable Responses in Acute Graft-vs-Host Disease

January 10th 2025

CAR T-Cell Therapy Debate in Leukemia/Lymphoma Subtypes
CAR T-Cell Therapy Debate in Leukemia/Lymphoma Subtypes

January 1st 2025

3 Things You Should Know About Hemolytic Anemias
3 Things You Should Know About Hemolytic Anemias

December 20th 2024

NX-5948 Earns Fast Track Designation in R/R Waldenström Macroglobulinemia
NX-5948 Earns Fast Track Designation in R/R Waldenström Macroglobulinemia

December 19th 2024